Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma

ErbB3 has been widely implicated in treatment resistance, but its role as a primary treatment target is less clear. Canonically ErbB3 requires EGFR or ErbB2 for activation, whereas these two established treatment targets are thought to signal independently of ErbB3. In this study, we show that ErbB3...

Descripción completa

Detalles Bibliográficos
Autores principales: Redlich, Nathan, Robinson, Anthony M., Nickel, Kwangok P., Stein, Andrew P., Wheeler, Deric L., Adkins, Douglas R., Uppaluri, Ravindra, Kimple, Randall J., Van Tine, Brian A., Michel, Loren S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849045/
https://www.ncbi.nlm.nih.gov/pubmed/29305574
http://dx.doi.org/10.1038/s41419-017-0029-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849045/
https://www.ncbi.nlm.nih.gov/pubmed/29305574
http://dx.doi.org/10.1038/s41419-017-0029-0

Ejemplares similares